<SEC-DOCUMENT>0001193125-24-260405.txt : 20241118
<SEC-HEADER>0001193125-24-260405.hdr.sgml : 20241118
<ACCEPTANCE-DATETIME>20241118064553
ACCESSION NUMBER:		0001193125-24-260405
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241118
DATE AS OF CHANGE:		20241118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		241469727

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d828431d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cvs="http://www.cvshealth.com/20241112" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2024-11-12_to_2024-11-12">CVS HEALTH Corp</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-277">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-11-12_to_2024-11-12">0000064803</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="cvs-20241112.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-11-12_to_2024-11-12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-12</xbrli:startDate> <xbrli:endDate>2024-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-288">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(D)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt:datemonthdayyearen" id="ixv-289">November 12, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img src="g828431g1116064733982.jpg" alt="LOGO"/></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">CVS HEALTH CORPORATION</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:stateprovnameen" id="ixv-290">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-291">001-01011</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-292">05-0494040</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-293">One CVS Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-294">Woonsocket</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:stateprovnameen" id="ixv-295">Rhode Island</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-296">02895</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices, and Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-297">(401)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-298">765-1500</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name, former address and former fiscal year, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:boolballotbox" id="ixv-299">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:boolballotbox" id="ixv-300">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:boolballotbox" id="ixv-301">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communication pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communication pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-303">Common Stock, par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-304">CVS</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:exchnameen" id="ixv-305">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-11-12_to_2024-11-12" format="ixt-sec:boolballotbox" id="ixv-306">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2024, CVS Health Corporation (the &#8220;Company&#8221;) entered into a confidentiality agreement (the &#8220;Confidentiality Agreement&#8221;) with Glenview Capital Management, LLC (&#8220;Glenview&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Confidentiality Agreement provides for, among other things, the sharing of certain of the Company&#8217;s confidential information with Glenview and imposes confidentiality and related obligations on Glenview and its affiliates and representatives with respect to such information. Pursuant to the Confidentiality Agreement, the Company also agreed to increase the size of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) by four and to appoint Leslie Norwalk, Larry Robbins, Guy Sansone and Doug Shulman to the Board. The Confidentiality Agreement provides that the Company will nominate each of Ms.&#160;Norwalk, Mr.&#160;Robbins, Mr.&#160;Sansone and Mr.&#160;Shulman for election at the Company&#8217;s 2025 annual meeting of stockholders and use its reasonable best efforts to cause their election at such annual meeting. The Company also agreed to appoint Ms.&#160;Norwalk to the Health Services and Technology (&#8220;HS&amp;T&#8221;) Committee of the Board and Mr.&#160;Sansone to the Audit Committee of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Confidentiality Agreement, Glenview and its affiliates and representatives have agreed to abide by certain customary standstill restrictions, which remain in effect until the thirtieth day prior to the commencement of the stockholder director nomination window for the Company&#8217;s 2026 annual meeting of stockholders, subject to earlier termination in certain limited circumstances as set forth in the Confidentiality Agreement. The Company and Glenview have also agreed to certain <span style="white-space:nowrap">non-disparagement</span> obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Confidentiality Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth in Item 1.01 is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2024, Ms.&#160;Norwalk, Mr.&#160;Robbins, Mr.&#160;Sansone and Mr.&#160;Shulman were appointed to the Board. In connection with the appointments of Mr.&#160;Robbins, Ms.&#160;Norwalk, Mr.&#160;Sansone and Mr.&#160;Shulman, the size of the Board was increased from 12 to 16 members. Ms.&#160;Norwalk was appointed to the HS&amp;T Committee of the Board, Mr.&#160;Sansone was appointed to the Audit Committee of the Board and Mr.&#160;Shulman was appointed to the Management Planning and Development (&#8220;MP&amp;D&#8221;) Committee of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the Confidentiality Agreement, there were no arrangements or understandings pursuant to which Ms.&#160;Norwalk, Mr.&#160;Robbins, Mr.&#160;Sansone or Mr.&#160;Shulman were appointed to the Board. The Company and its subsidiaries have paid Ms.&#160;Norwalk in the aggregate approximately $159,170 in 2023 and currently owe approximately $210,120 from January&#160;1, 2024 through November&#160;15, 2024 for her service as an expert witness in certain litigation involving the Company and its subsidiaries. It is expected that Ms.&#160;Norwalk will receive payments from the Company and its subsidiaries for her continued service as an expert witness in currently pending litigation. Except as set forth in the immediately preceding sentences, since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms.&#160;Norwalk, Mr.&#160;Robbins, Mr.&#160;Sansone or Mr.&#160;Shulman that would be reportable under Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&#160;Norwalk, Mr.&#160;Robbins, Mr.&#160;Sansone and Mr.&#160;Shulman will participate in the same compensation program as each of the Company&#8217;s other <span style="white-space:nowrap">non-employee</span> directors. This program for the most recent fiscal year is described under <span style="white-space:nowrap">&#8220;Non-Employee</span> Director Compensation&#8221; in the Company&#8217;s proxy statement for its 2024 annual meeting of stockholders filed with the Securities and Exchange Commission on April&#160;5, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on November&#160;12, 2024, the MP&amp;D Committee approved an increase in the compensation of J. David Joyner, in connection with his appointment as President and Chief Executive Officer of the Company on October&#160;17, 2024, effective as of such date. As increased, Mr.&#160;Joyner&#8217;s annual total direct compensation opportunity will consist of an annual base salary of $1,500,000, a target annual bonus opportunity of $3,000,000 (equal to 200% of his base </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
salary) and a target long-term annual incentive award opportunity equal to $14,500,000. Also on November&#160;12, 2024, the MP&amp;D Committee approved an increase in the compensation of Prem S. Shah, in connection with his appointment as Executive Vice President and Group President on November&#160;6, 2024, effective as of such date. As increased, Mr.&#160;Shah&#8217;s annual total direct compensation opportunity will consist of an annual base salary of $1,100,000, a target annual bonus opportunity of $1,925,000 (equal to 175% of his base salary) and a target long-term annual incentive award opportunity of $9,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, on November&#160;12, 2024, the MP&amp;D Committee approved one time promotion stock awards for each of Mr.&#160;Joyner and Mr.&#160;Shah and a <span style="white-space:nowrap">one-time</span> retention award for Tilak Mandadi, the Company&#8217;s Chief Digital, Data, Analytics and Technology Officer, each with a grant date of November&#160;30, 2024. The awards to Mr.&#160;Joyner and Mr.&#160;Shah are in the form of premium-priced stock options to acquire shares of Company common stock, with a grant date value of $12,000,000, in the case of Mr.&#160;Joyner, and $6,000,000, in the case of Mr.&#160;Shah. The premium-priced stock options will have an exercise price equal to 120% of the closing price of the Company&#8217;s common stock on November&#160;29, 2024 and vest in three equal annual installments during the three years following the grant date, generally subject to the executive&#8217;s continued employment on each vesting date. Mr.&#160;Mandadi&#8217;s award is in the form of time-vesting restricted stock units in respect of Company common stock, with a grant date value of $3,000,000 and vests in three equal annual installments during the three years following the grant date subject to a <span style="white-space:nowrap">one-year</span> post-vest holding period, generally subject to his continued employment on each vesting date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01. Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;18, 2024, the Company issued a press release announcing the appointment of Ms.&#160;Norwalk, Mr.&#160;Robbins, Mr.&#160;Sansone and Mr.&#160;Shulman to the Board and the Company&#8217;s entry into the Confidentiality Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2 of Form <span style="white-space:nowrap">8-K,</span> the information in this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d) Exhibits</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:9%"/>
<td style="width:88%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit&#160;Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828431dex101.htm">Confidentiality Agreement, dated November&#160;17, 2024, by and between the Company and Glenview Capital Management, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828431dex991.htm">Press Release, dated November&#160;18, 2024 (furnished under Item 7.01). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: November&#160;18, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">CVS HEALTH CORPORATION</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kristina V. Fink</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Kristina V. Fink</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Senior Vice President, Chief Governance Officer and Corporate Secretary</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-3- </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d828431dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CVS Health Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;17, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glenview Capital
Management, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">767 Fifth Avenue, 44th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
10153 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mark Horowitz </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:
mark@glenviewcapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health
Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;), and Glenview Capital Management, LLC (together with its Affiliates, &#147;<U>Counterparty</U>&#148; or &#147;<U>you</U>&#148;, and together with the Company, each a
&#147;<U>party</U>&#148; and collectively the &#147;<U>parties</U>&#148;) entered into a letter agreement, dated October&nbsp;11, 2024 (the &#147;<U>Original NDA</U>&#148;), governing the sharing of certain information concerning the Company and its
subsidiaries and certain confidentiality and other obligations in connection therewith. In connection with the appointment of the four persons described in the form of press release attached to this agreement as <U>Exhibit A</U> and pursuant to
<U>Section</U><U></U><U>&nbsp;8</U>, including Larry Robbins (the &#147;<U>Glenview Appointee</U>&#148;), to the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), the parties desire to amend and restate the Original NDA in its
entirety as set forth herein. In consideration of the covenants and agreements set forth herein, the receipt and sufficiency of which are hereby acknowledged, the Original NDA is hereby amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Confidential Information</U>. The Company understands and agrees (for your benefit and for the benefit of the Glenview Appointee) that,
subject to the terms of, and in accordance with this agreement, the Glenview Appointee may confidentially disclose information obtained while serving as a member of the Board to you, including your Representatives, and may confidentially discuss
such information with such persons, subject to the terms and conditions of this agreement. As a result, you and your Representatives may receive certain <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company. This
information is proprietary to the Company and may include strategic, business or financial planning information, intellectual property, financial results, projections and forecasts or advice received by such parties or individuals from the
Company&#146;s attorneys, accountants, consultants or other advisors, trade secrets, information which the Company has obtained from third parties and with respect to which the Company is obligated or expected to maintain confidentiality. You agree
to treat, and to cause your Representatives to treat, all information concerning the Company and its subsidiaries that is confidential, <FONT STYLE="white-space:nowrap">non-public</FONT> or proprietary (whether prepared by the Company, its
Affiliates, subsidiaries, Representatives or otherwise, and whether oral, written, electronic or otherwise), including, without limitation, all information the Glenview Appointee learns in his capacity as a director of the Company and all
discussions or matters considered in meetings of the Board or Board committees (such information, the &#147;<U>Confidential Information</U>&#148;), in accordance with the provisions of this agreement. For the avoidance of doubt, the term
&#147;Confidential Information&#148; includes information ascertained by Counterparty or its Representatives through discussions with directors, employees or other Representatives of the Company, together with all analyses, summaries, notes,
forecasts, studies, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data and other documents and materials in whatever form maintained whether prepared by either party or its Representatives or others, which contain or reflect, or are generated from, any such
information, including information provided under the Original NDA. For the avoidance of doubt, the existence of this agreement, the entry into and negotiations regarding such agreement and the fact that Confidential Information has been, or may be,
made available to Counterparty or its Representatives shall not constitute Confidential Information. Notwithstanding any other provision hereof, the term &#147;Confidential Information&#148; does not include any information that (i)&nbsp;is or
becomes available to Counterparty or its Representatives on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a source other than the Company or any of its Representatives, <I>provided </I>that such source is not known by
Counterparty or such Representative to be bound by confidentiality obligation to the Company that prohibits such disclosure, (ii)&nbsp;is or becomes publicly available other than as a result of disclosure, directly or indirectly, by Counterparty or
any of its Representatives, (iii)&nbsp;is already in Counterparty&#146;s or its Representative&#146;s possession prior to being furnished by the Company or its Representatives, <I>provided</I> that such information is not known by Counterparty or
such Representative to be subject to a confidentiality obligation to the Company or (iv)&nbsp;is independently acquired and developed by Counterparty or its Representative without use of or reference to the Confidential Information. For purposes of
this agreement, the term &#147;<U>Affiliate</U>&#148; (and any plurals thereof) have the meanings ascribed to such terms under Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated by the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) under the Securities Exchange Act of 1934 (the &#147;<U>Exchange Act</U>&#148;) and shall include persons or entities that after the date hereof become Affiliates of any applicable person or entity referred to in this
agreement; and the term &#147;<U>Representatives</U>&#148; with respect to a party shall mean such party&#146;s Affiliates and the managing members, principals, partners (other than a partner who is solely a limited partner), directors, officers,
general partners, employees and attorneys of such party and of its Affiliates. Counterparty and its Representatives who receive any Confidential Information hereunder shall keep the Confidential Information strictly confidential and shall not
disclose, directly or indirectly, any of the Confidential Information in any manner without the prior written consent of the Company except as provided herein. Notwithstanding the foregoing, Counterparty may disclose Confidential Information on a
strictly confidential basis to its Representatives (x)&nbsp;who need to know such information for the purpose of advising Counterparty with respect to the Purpose (as defined below), and (y)&nbsp;who are informed by Counterparty of the confidential
nature of the Confidential Information and who agree or are obligated to keep such information confidential in accordance with the terms hereof (the &#147;<U>Specified Counterparty Personnel</U>&#148;). Counterparty agrees (1)&nbsp;that the
Confidential Information shall be used solely for the purpose of monitoring and managing Counterparty&#146;s investment in the Company (the &#147;<U>Purpose</U>&#148;), and (2)&nbsp;to be responsible for any breach of any of the provisions of this
agreement by Counterparty or any of its Representatives (including Specified Counterparty Personnel). In the event that the Company&#146;s legal counsel designates any materials or information provided to the Glenview Appointee as subject to the
attorney-client privilege by labeling it &#147;Privileged and Confidential&#148; or otherwise indicating such privilege, then the Glenview Appointee shall not be permitted to share any such information with Counterparty or any of its Representatives
unless approved by the Company&#146;s legal counsel. At the request of Counterparty, the Company will consider in good faith commercially reasonable arrangements (including providing redacted copies of materials) that would allow the Glenview
Appointee the ability to provide such materials without jeopardizing legal privilege. Notwithstanding anything to the contrary set forth in this agreement, nothing in this agreement shall restrict or limit the ability of Counterparty from engaging
in a proxy contest from and after the Sunset Date (as defined below), it being agreed that Counterparty and its Representatives shall be entitled to disclose that portion of (and only such portion of) Confidential Information required to be
disclosed by applicable law in order to engage in such a proxy contest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT></U>. In the event that
Counterparty or any of its Representatives are legally required to disclose any Confidential Information (or to make any disclosure otherwise prohibited hereby) under the terms of a subpoena or order issued by a court or governmental or regulatory
body of competent jurisdiction, (a)&nbsp;Counterparty and the Specified Counterparty Personnel agree to, except to the extent prohibited by law, as promptly as practicable notify the Company of the existence, terms and circumstances surrounding such
a requirement so that the Company may seek an appropriate protective order or other appropriate remedy at its sole expense and/or consider waiving Counterparty&#146;s or the Specified Counterparty Personnel&#146;s compliance with the provisions of
this agreement (and in which event Counterparty shall cooperate with the Company&#146;s reasonable requests, at the Company&#146;s sole expense, in connection with seeking a protective order or other relief to prevent the disclosure of the
Confidential Information), and (b)&nbsp;if such protective order or waiver is not obtained and disclosure of such information is legally required on the advice of Counterparty&#146;s outside legal counsel, (x)&nbsp;Counterparty and the Specified
Counterparty Personnel agree to exercise reasonable best efforts, at the Company&#146;s request and sole expense, to obtain an order or other reliable assurance that confidential treatment will be accorded to the disclosed Confidential Information,
and (y)&nbsp;Counterparty and the Specified Counterparty Personnel shall be permitted to disclose only that portion of the Confidential Information that is so legally required to be disclosed on the advice of Counterparty&#146;s outside legal
counsel, <I>provided</I> that Counterparty and the Specified Counterparty Personnel shall preview with the Company, except to the extent prohibited by law, reasonably prior to making any such disclosure, the specific disclosures that Counterparty
and the Specified Counterparty Personnel would make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>No Representations or License</U>. Counterparty acknowledges that none of the
Company or any of its Representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of the Confidential Information, and none of the Company or any of its Representatives shall have any liability to
Counterparty or its Representatives relating to or resulting from the use of the Confidential Information or any errors therein or omissions therefrom (it being understood that the foregoing shall not be deemed to limit any director&#146;s ability
to rely on information provided to such director pursuant to any provision of the General Corporation Law of the State of Delaware, including, without limitation, Section&nbsp;141(e) thereof). All Confidential Information shall remain the property
of the Company, and neither Counterparty nor its Representatives shall by virtue of the Company&#146;s disclosure of and/or Counterparty&#146;s use of any Confidential Information acquire any rights with respect thereto, all of which rights
(including any intellectual property rights) shall remain exclusively with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Securities Laws</U>. Counterparty hereby
acknowledges that it is aware, and that it will advise its Representatives who become aware of the matters that are the subject of this agreement, that the United States securities laws prohibit any person who has received from an issuer material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information from purchasing or selling securities of such issuer or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is
likely to purchase or sell such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Return or Destruction</U>. At any time after the date on which the Glenview Appointee
no longer serves on the Board, if requested by the Company, Counterparty and its Representatives shall promptly, and in any event within five business days of such request, either (at Counterparty&#146;s option)&nbsp;(a) destroy or cause to be
destroyed all Confidential Information in the possession of Counterparty or its Representatives, including all copies thereof, or (b)&nbsp;deliver or cause to be delivered to the Company all Confidential Information in the possession of Counterparty
or its Representatives, including all copies thereof. Notwithstanding the foregoing, the obligation to return or destroy Confidential Information shall not cover information that is (i)&nbsp;automatically maintained on routine computer system backup
storage devices, (ii)&nbsp;maintained pursuant to bona fide internal document retention policies of Counterparty or its Representatives, or (iii)&nbsp;retained to comply with applicable laws or regulations, in each case as long as such <FONT
STYLE="white-space:nowrap">backed-up</FONT> information is not used, disclosed or otherwise recovered from such backup devices other than by IT or legal compliance personnel. In such event, all oral or retained Confidential Information shall remain
subject to the terms of this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Standstill</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Until the Sunset Date (as defined below), you shall not, and shall cause your Affiliates and Representatives
not to, directly or indirectly, alone or in concert with others, absent prior written consent by the Board: (i)&nbsp;call or seek to call a meeting of the Company&#146;s stockholders or action by written consent, (ii)&nbsp;call or seek (including
through any &#147;withhold&#148; or similar campaign) the removal of any member of the Board, (iii)&nbsp;seek the election or appointment to, or representation on, the Board or nominate or propose the nomination of, or recommend the nomination of,
any candidate to the Board, (iv)&nbsp;submit, initiate, make or be a proponent of any stockholder proposal (x)&nbsp;for consideration at, or bring any other business before, any meeting of stockholders of the Company or (y)&nbsp;through action by
written consent, (v)&nbsp;engage in any solicitation of proxies or consents with respect to the election or removal of directors of the Company or any other matter or proposal relating to the Company or become a &#147;participant&#148; (as such term
is defined in Instruction 3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in any such solicitation of proxies or consents, (vi)&nbsp;take any action in support of, or make any proposal or request in furtherance of, controlling or
changing the Board or management of the Company or publicly comment on any proposal regarding any tender offer, exchange offer, merger, consolidation, acquisition, business combination, recapitalization, restructuring, liquidation, dissolution, sale
or other disposition of a material asset or business or similar extraordinary transaction involving the Company (including its subsidiaries and joint ventures or any of their respective securities or assets) (each, an &#147;<U>Extraordinary
Transaction</U>&#148;), (vii) form, join or participate in any &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act), or enter into any negotiations, agreements, arrangements or understandings with or knowingly assist
any third party with respect to the matters set forth in this <U>Section</U><U></U><U>&nbsp;6</U> or (viii)&nbsp;request any waiver or amendment of the terms of this agreement other than through <FONT STYLE="white-space:nowrap">non-public</FONT>
communications with the Company that would not trigger public disclosure obligations for any party or any of their respective Representatives. For purposes of this agreement, the term &#147;<U>Sunset Date</U>&#148; shall mean 12:01 a.m. Eastern Time
on the thirtieth (30th) day prior to the commencement of the stockholder director nomination window (for the avoidance of doubt, excluding a nomination pursuant to Section&nbsp;1.11 of the Company&#146;s
<FONT STYLE="white-space:nowrap">By-Laws)</FONT> pursuant to the terms of the Company&#146;s <FONT STYLE="white-space:nowrap">By-Laws</FONT> for election to the Board at the Company&#146;s 2026 annual meeting of stockholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The restrictions in this <U>Section</U><U></U><U>&nbsp;6</U> shall terminate automatically upon the earliest of
the following: (i)&nbsp;a failure to appoint or nominate the New Directors to the Board in accordance with <U>Section</U><U></U><U>&nbsp;8(a)</U>, or to the applicable committees of the Board in accordance with <U>Section</U><U></U><U>&nbsp;8(d)</U>
or to issue the Press Release in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, in each case upon five (5)&nbsp;business days&#146; written notice by Counterparty to the Company if such breach has not been cured within such notice period,
<I>provided</I>, that Counterparty is not in material breach of this agreement at the time such notice is given or prior to the end of the notice period; (ii)&nbsp;the Company&#146;s entry into a definitive agreement with respect to any
Extraordinary Transaction that would result in the acquisition by any person or group of more than 50% of the voting securities of the Company or assets having an aggregate value exceeding 50% of the aggregate enterprise value of the Company; and
(iii)&nbsp;the commencement of any tender or exchange offer (by any person or group other than Counterparty or its Affiliates) which, if consummated, would constitute an Extraordinary Transaction that would result in the acquisition by any person or
group of more than 50% of the voting securities of the Company, where the Company files with the SEC a Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> (or amendment thereto) that does not recommend that its stockholders reject such tender or
exchange offer (it being understood that nothing herein will prevent the Company from issuing a &#147;stop, look and listen&#148; communication pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated by the SEC under the
Exchange Act in response to the commencement of any tender or exchange offer). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary contained in this agreement (including but not limited to the
restrictions in this <U>Section</U><U></U><U>&nbsp;6</U>), Counterparty shall not be prohibited or restricted from: (i)&nbsp;communicating privately with the Board, any member of senior management of the Company (including the Company&#146;s Chief
Executive Officer, Chief Financial Officer, and General Counsel) or any director of the Company regarding any matter, so long as any such communication would not reasonably be expected to require any public disclosure of such communications by
Counterparty or its Affiliates, the Company or its Affiliates or any third party; (ii)&nbsp;making any factual statement required to comply with any subpoena or other legal process (so long as such process or request did not arise as a result of
discretionary acts by Counterparty or any of its Affiliates or Representatives); or (iii)&nbsp;privately communicating to Counterparty&#146;s or its controlled Affiliates&#146; investors or potential investors regarding the Company; <I>provided</I>,
that any such communications to investors or potential investors (A)&nbsp;are subject to reasonable confidentiality obligations of such investors or potential investors and are not reasonably expected to be publicly disclosed, (B)&nbsp;are not made
with an intent to circumvent any of the restrictions in this agreement or otherwise in bad faith and (C)&nbsp;do not include the disclosure of Confidential Information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this agreement (including but not limited to the restrictions in
this <U>Section</U><U></U><U>&nbsp;6</U>), any action, statement or disclosure by Counterparty or any of its Representatives taken after the Sunset Date that would have been restricted by the restrictions in this <U>Section</U><U></U><U>&nbsp;6</U>
if such action, statement or disclosure had been taken before the Sunset Date shall not be, and shall be deemed not to involve, a breach of the restrictions in this <U>Section</U><U></U><U>&nbsp;6</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Until the Sunset Date,
the Company, on the one hand, and Counterparty, on the other hand, shall each refrain from making, and shall cause their Affiliates and Representatives not to make, any statement, whether written or oral and including any statements to stockholders,
analysts or representatives of the media, that constitutes an ad hominem attack on, or that otherwise disparages, defames, slanders, impugns or is reasonably likely to damage the reputation of Counterparty or the Company, respectively, or any of
their respective Affiliates and Representatives. The foregoing shall not prevent (i)&nbsp;the making of any factual statement in the event that the Company or any of its Representatives or Counterparty or any of its Representatives is required to
make that statement by applicable subpoena, legal process or other legal requirement or (ii)&nbsp;to the extent that any party breaches this <U>Section</U><U></U><U>&nbsp;7</U>, the other party that is the subject of the breaching statement
responding factually to such breaching statement. If prior to the Sunset Date the Glenview Appointee, Counterparty or any Specified Counterparty Personnel expect or intend to make any public appearance, presentation or speech that relates in whole
or in part to the Company or any of its Affiliates, directors, officers or employees, the Glenview Appointee or Counterparty, as applicable, shall provide to the Company copies of all presentations, scripts and speeches intended to be used during
such appearance, presentation or speech reasonably in advance and will incorporate in good faith all reasonable comments provided by the Company thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Board of Directors</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Appointment; Nomination</U>. As of the date of this agreement, the Board and all applicable committees
thereof have taken all such actions as are necessary to increase the size of the Board by four (4)&nbsp;directors and the Board has appointed the Glenview Appointee and Leslie Norwalk, Guy Sansone and Doug Shulman (collectively with the Glenview
Appointee, the &#147;<U>New Directors</U>&#148;) to the Board. The Board shall nominate each of the New Directors for election to the Board at the Company&#146;s 2025 annual meeting of stockholders (the &#147;<U>2025 Annual Meeting</U>&#148;). The
Company shall use its reasonable best efforts to cause the election of each of the New Directors at the 2025 Annual Meeting. These reasonable best efforts will include listing such persons in the proxy statement and proxy card prepared, filed and
delivered in connection with such meeting and recommending that the Company&#146;s stockholders vote in favor of the election of such individuals and otherwise supporting each of them for election in a manner no less rigorous and favorable than the
manner in which the Company supports its other nominees in the aggregate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Company Policies</U>. The parties acknowledge that the New Directors, upon election or appointment to the
Board, will be governed by the same protections and obligations regarding confidentiality, conflicts of interest, related person transactions, fiduciary duties, codes of conduct, trading and disclosure policies, director resignation policy, and
other governance guidelines and policies of the Company as other directors of the Company (collectively, &#147;<U>Company Policies</U>&#148;), and shall have the same rights and benefits, including with respect to insurance, indemnification, books
and records, compensation and fees, as are applicable to all <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of the Company. The Company represents and warrants that all Company Policies currently in effect are publicly available on
the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company&#146;s website or have been provided to Counterparty or its counsel. The Company further acknowledges and agrees that, except for restrictions set forth in the Company&#146;s Corporate
Governance Guidelines and its insider trading policy, in each case, with respect to prohibiting insider trading and confidentiality, none of the restrictions contained in the Company Policies applicable to the Glenview Appointee (as a director),
including any restrictions on pledging or making purchases on margin of, or entering into derivative or hedging arrangements (including options) with respect to, securities of the Company, or otherwise trading the Company&#146;s securities during
open window periods (it being understood and agreed that Counterparty shall be free to trade in the Company&#146;s securities in accordance with federal and state securities laws during open trading window periods without the prior approval of the
Company, and shall only be prohibited from trading during blackout periods generally applicable to all of the Company&#146;s directors and senior insiders), shall be deemed to apply to Counterparty (other than Mr.&nbsp;Robbins in his capacity as a
director of the Company). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Committees</U>. The Board has resolved to appoint (concurrently with their appointment to the Board) Leslie
Norwalk to the Health Services and Technology Committee of the Board and Guy Sansone to the Audit Committee of the Board. Larry Robbins shall be eligible to serve on a committee of the Board as determined by the Board. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Public Announcements</U>. Not later than 8:30 a.m. Eastern Time on November&nbsp;18, 2024, the Company shall issue a press release in
the form attached to this agreement as <U>Exhibit A</U> (the &#147;<U>Press Release</U>&#148;). Substantially concurrently with the issuance of the Press Release, the Company shall file with the SEC a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (the &#147;<U>Form <FONT STYLE="white-space:nowrap">8-K</FONT></U>&#148;) disclosing its entry into this agreement and including a copy of this agreement and the Press Release as exhibits thereto. The Form <FONT
STYLE="white-space:nowrap">8-K</FONT> shall be consistent with the Press Release and the terms of this agreement, and shall be in form and substance reasonably acceptable to the Company and Counterparty. The Company shall provide Counterparty and
its Representatives with a copy of the Form <FONT STYLE="white-space:nowrap">8-K</FONT> prior to its filing with the SEC and shall consider any timely comments of Counterparty and its Representatives. Neither of the Company or any of its Affiliates
nor Counterparty or any of its Affiliates shall make any public statement regarding the subject matter of this agreement or the matters set forth in the Press Release prior to the issuance of the Press Release without the prior written consent of
the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Specific Performance; Remedies</U>. Each party agrees that the other party would be irreparably injured by a
breach or threatened breach of this agreement by such party or its Representatives and monetary remedies are an inadequate remedy to protect against any actual or threatened breach or continuation of any breach of this agreement. Therefore, without
prejudice to any other rights or remedies otherwise available under this agreement, each party agrees to the granting of specific performance of this agreement and injunctive or other equitable relief in favor of the other party as a remedy for any
such actual, threatened or anticipated breach, without proof of actual damages. Each party further agrees to waive any requirement for the securing or posting of any bond in connection with any such remedy. Such remedy shall not be deemed to be the
exclusive remedy for either party or its Representatives&#146; breach of this agreement, but shall be in addition to all other remedies available at law or equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Dual Representative</U>. The Company acknowledges that certain directors, officers,
Representatives and employees who serve on the board of directors (or similar governing body) of one or more of Counterparty&#146;s Affiliates may also serve as a Representative of Counterparty in another position or role (a &#147;<U>Dual
Representative</U>&#148;) and no such Affiliates or Representatives will be deemed to have received such Confidential Information solely as a result of such dual role of any such Dual Representative, <I>provided</I> that such Dual Representative
shall not have directly or indirectly disclosed any Confidential Information to such Affiliate or Representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Governing Law;
Venue</U>. This agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to the choice of law principles of such state. Each party hereto hereby irrevocably and unconditionally submits
to (a)&nbsp;the exclusive jurisdiction of the Delaware Court of Chancery, or in the event that the Delaware Court of Chancery lacks jurisdiction, any federal court in the State of Delaware, for purposes of any suit, action or other proceeding
arising out of this agreement that is brought by or against a party, and (b)&nbsp;the exclusive venue of such suit, action or proceeding in the Delaware Court of Chancery, or in the event that the Delaware Court of Chancery lacks jurisdiction, any
federal court in the State of Delaware. Each party hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this agreement in the above named courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Miscellaneous</U>. This agreement supersedes all prior oral or written agreements or understandings that may exist between or among the
parties hereto in respect of any Confidential Information or the other subject matter hereof. If any term, provision, covenant or restriction of this agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this agreement shall remain in full force and effect to the fullest extent permitted by law and shall in no way be affected, impaired or invalidated. This agreement may only be
amended with the prior written consent of both parties, and neither party may assign any of its rights or obligations under this agreement without the prior written consent of the other party. Any waiver of its rights hereunder by a party shall be
required in advance and in writing. It is understood and agreed that no failure or delay by either party in exercising any right, power or privilege under this agreement shall operate as a waiver thereof, nor shall any single or partial exercise
thereof preclude any other or future exercise thereof or the exercise of any other right, power or privilege under this agreement. This agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which
shall constitute the same agreement and shall become a binding agreement when a counterpart has been signed by each party and delivered to the other party. Signatures of the parties transmitted by facsimile, PDF or other electronic file shall be
deemed to be their original signatures for all purposes and the exchange of copies of this agreement and of signature pages by facsimile transmission, PDF or other electronic file shall constitute effective execution and delivery of this agreement
as to the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Term</U>. Except as otherwise expressly provided herein, this agreement shall expire and be of no further force
or effect from and after the date that is eighteen (18)&nbsp;months after the date that the Glenview Appointee no longer serves on the Board. The expiration or termination of this agreement will not affect the liability of any party for any prior
breach of any provision hereof prior to such expiration or termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Expenses</U>. Promptly following the execution and delivery of this agreement, the
Company shall reimburse Counterparty for reasonable documented fees, costs and expenses Counterparty has incurred arising from or relating to Counterparty&#146;s engagement with the Company in an amount not to exceed the amount specified in the
email from Cadwalader, Wickersham&nbsp;&amp; Taft LLP to Wachtell, Lipton, Rosen&nbsp;&amp; Katz with the subject line, &#147;Expense Cap.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Notice</U>. All notices, consents, requests, instructions, approvals and other communications provided for herein and all legal process
in regard hereto shall be in writing and shall be deemed validly given, made or served, (a)&nbsp;if given by email, when such email is sent to the email address set forth below (except in the event of any &#147;bounceback&#148; or similar <FONT
STYLE="white-space:nowrap">non-transmittal</FONT> message) or (b)&nbsp;if given by any other means, when actually received during normal business hours at the address specified in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">One CVS Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Woonsocket,&nbsp;Rhode Island&nbsp;02895 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8194;&nbsp;Samrat Khichi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8202;Sam.Khichi@cvshealth.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wachtell, Lipton, Rosen&nbsp;&amp; Katz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">51 West 52nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &#8195;&#8194;Jacob A. Kling </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8202;JAKling@wlrk.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to Counterparty: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glenview Capital Management, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">767 Fifth Avenue, 44th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10153 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &#8195;&#8194;Mark Horowitz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8202;mark@glenviewcapital.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cadwalader, Wickersham&nbsp;&amp; Taft LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">200 Liberty Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10281 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &#8195;&#8194;Richard M. Brand </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8194;Gregory P. Patti </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8202;Richard.Brand@cwt.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8194;Greg.Patti@cwt.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please confirm your agreement with the foregoing by signing and returning this agreement to
the undersigned, whereupon this agreement shall become a binding agreement between Counterparty and the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CVS Health Corporation</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Samrat Khichi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Name:&#8201;&#8202;Samrat Khichi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Title:&#8194;&#8201;&#8202;Executive Vice President, Chief Policy Officer and General
Counsel</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and agreed</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as of the date first written above:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Glenview Capital Management, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mark Horowitz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Name:&#8201;&#8202;Mark Horowitz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Title:&#8194;&#8201;&#8202;Co-President</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Press Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Filed separately as Exhibit 99.1 to the Current Report on Form 8-K</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d828431dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRESS RELEASE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CVS Health Announces Board Appointments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointments follow productive engagement with Glenview Capital Management </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WOONSOCKET, RI (November 18, 2024) &#150; The Board of Directors of CVS Health (NYSE: CVS) today announced the appointment of four new board members: Leslie
Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In our discussions with
the leadership at Glenview, we agreed that we can deliver greater value from our integrated businesses to all of our stakeholders, including our customers, consumers, colleagues, and shareholders,&#148; said Roger Farah, Executive Chairman of the
Board, CVS Health. &#147;Having Leslie, Larry, Guy, and Doug join our Board will add new thinking and deep market and industry experiences as we focus on driving greater financial and operational performance.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As we build momentum across our integrated model, we continue to take actions that are positive for our long-term success, while driving innovation and
performance in our individual businesses and at CVS Health overall,&#148; said David Joyner, president and chief executive officer of CVS Health. &#147;Adding four experienced thought leaders to our Board further sharpens our focus on executing
against our strategy to build a world of health around every consumer, as we improve total cost of care and customer experience in health care.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We welcome the opportunity to join the Board, roll up our sleeves and lock arms with the Board and leadership team to drive long-term, sustainable value
through continued customer-centric offerings, commitment to compliance and quality, disciplined underwriting and risk management, aligned incentives, and optimal capital allocation,&#148; said Larry Robbins, CEO of Glenview Capital
Management.&nbsp;&#147;We appreciate the Board engaging with us on a cooperative basis that allows all energies to be productively dedicated towards further strengthening this iconic company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Norwalk will join the Health Services Committee, Sansone will join the Audit Committee, and Shulman will join the Management Planning and Development
Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With these four new directors, the Board now comprises 16 members. In connection with the Board appointments, CVS Health and Glenview entered
into a confidentiality agreement under which Glenview has agreed to customary confidentiality, standstill and other provisions. The confidentiality agreement will be filed on a Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the U.S.
Securities and Exchange Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Leslie Norwalk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Norwalk serves as Strategic Counsel to healthcare companies through her roles at Epstein Becker Green, EBG Advisors, and National Health Advisors. She also
advises several private equity firms and holds board positions at Arvinas, ModivCare, Neurocrine Biosciences, Globus Medical, as well as multiple privately held healthcare corporations. Her board experience includes previous roles with health
insurers and pharmacy benefit managers. In the George W. Bush administration, Norwalk held several positions at the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), including Acting Administrator, where she oversaw Medicare, Medicaid, the
State Children&#146;s Health Insurance Program, Survey and Certification, and other federal healthcare initiatives, notably implementing the Medicare Prescription Drug Benefit. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Larry Robbins </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robbins is the Founder, Portfolio Manager, and CEO of Glenview Capital Management and has 30 years of experience as an institutional investor with a
significant healthcare focus.&nbsp;He brings extensive Board and leadership experience across both <FONT STYLE="white-space:nowrap">non-profit</FONT> and commercial enterprises as Board Chair of KIPP NYC and Array Education, past Board Chair of
Relay Graduate School of Education, Zearn and the Robin Hood Foundation and as Lead Independent Director of Butterfly Network.&nbsp;Robbins became a Certified Public Accountant in 1991.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Guy Sansone </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sansone is currently Chairman and CEO
of H2 Health, a leading regional provider of physical rehabilitation services and clinician staffing solutions. He brings more than 30 years of experience working as an advisor, investor and senior manager in companies where he helped to refine
long-term strategy, enhance operations, and implement organic and inorganic growth plans.&nbsp;Prior to founding H2, Sansone worked at Alvarez and Marsal for 21 years where he was the founder of the Healthcare Industry Group. His leadership roles
have been with companies across <FONT STYLE="white-space:nowrap">sub-sectors</FONT> of the healthcare landscape, with a particular focus on healthcare services. Sansone is Lead Independent Director of Pediatrix Medical Group, and serves on the board
of ChenMed. He has also served on a number of healthcare company boards, including Magellan, Brookdale Senior Living, and HealthPRO Heritage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Doug Shulman </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shulman has been the Chairman of OneMain Holdings, Inc. since January 2021, and has served as CEO since 2018. Shulman has significant
experience managing large, complex organizations at the intersection of technology, data and analytics. Previously he was Senior Executive Vice President, Global Head of Client Service Delivery and a member of the Executive Committee at BNY Mellon
from 2014 to 2018. Shulman was the Commissioner of the Internal Revenue Service from 2008 to 2012. Earlier in his career, he served in several executive positions, including Vice Chairman, at the Financial Industry Regulatory Authority and its
predecessor the NASD from 2000 to 2008, where he oversaw its multiple markets, corporate development, services and technology. Shulman currently serves on the Carnegie Foundation for the Advancement of Teaching Board of Trustees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CVS Health </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital
channels and over 300,000 dedicated colleagues &#151; including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health &#151; whether that&#146;s managing
chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system &#151; and their personal health care &#151; by improving
access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Glenview Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In its 24<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>&nbsp;year of operations, Glenview Capital is a long-term investment partnership focused on
fundamental investing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary statement concerning forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking
statements made by or on behalf of CVS Health. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual
results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (&#147;SEC&#148;) filings, including those set forth in the Risk Factors
section and under the heading &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; in our most recently filed Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended March&nbsp;31, 2024, June&nbsp;30, 2024 and September&nbsp;30, 2024 and our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS Health&#146;s forward-looking statements. CVS Health&#146;s forward-looking statements are and will be
based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking
statements, whether as a result of new information, future events, uncertainties or otherwise. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvs-20241112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/18/2024 4:39:54 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:cvs="http://www.cvshealth.com/20241112"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.cvshealth.com/20241112"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20241112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20241112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvs-20241112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/18/2024 4:39:54 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cvs-20241112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/18/2024 4:39:54 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cvs-20241112.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g828431g1116064733982.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g828431g1116064733982.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  3 )4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#*\:^.-0\2
MZR6226VL[=R+>%6*D$'[Q_VOY4:S\1=<UKP_;:3/.56,8GE0X:?TW?YY[UW'
MQ,^'7G";7M&A_>#+W5N@^]ZNH]?45Y!9V5SJ%[%9VL+2W$K;411R37DU?:0F
MTWN?H> >"Q&'A.$5:'?H_P"NOS/6/A+XUO9[Q/#E\7GC*,UO*QR8PHR5)],=
M/3I6!JVMZY\1?&)TJPNGBLVD988@Y5 B_P ;8ZG S^.*]0\#>!+;PKIC--MD
MU*=,32C^ '^%?:O(O!U]'X,^(>-5!BCA:2WE8C[N> ?ID#\ZVDIQA",WHSS:
M$\/5Q&(KX6-Y16GF];M+[OZ9?ETGQ?\ #S7+?[))<7<+ .5@#-'(N>59?\]:
MD\-ZI?:%\4[>SN;NZ-K)-Y0CGE8_)(N4R">OS+76^)OB]::=?0V^BPQ:BI7,
MDFX@ YX ]:YOXJVES::MH?B,P^3/<0H95'\$J8./UQ_P&E)1CK!WLRZ%2K7:
MIXJFHNI%J_5M>72VHOCC4M0USXI1:-87EQ%&K16N(I"HR>6/'IN/Y5S<]_<^
M*_%+VNJZR]C:[V1/-+,D(7A5VY]L9_.NF^%=K+K_ ([U'Q#<KDP[Y?822$X'
MY;J@U5_ _BC7IE<W6BWDC-YDL@ CWCKD=B34M.2Y[[LUISA0J?5U'X(J\DKM
M-[FWX$T?Q3HGB!%@OX;_ $1F*2;+C<NT]'"\[3T_E4VDZ596GQNU>-[NZ6&V
MM([N&.6]DV"60G<<%L$<].@K@_#ES<Z#\0K.TTC4/M<)NTAWQ$[)D8@'CZ$_
ME7>R>'M,\0_&[78=3MA.D6EV[(-Q&#DCM75A9)Q:70\+/:4HUHSDT^9=%;[U
MW)/BY!:7,.@74-[,L\FJV]FXM[MDS"Y.X84_3GK78:GXCT/P;9V=C=7$FX1A
M(($#33.JC&<<D].IK@?B'X.T+0;;P[=Z;9"&<Z]:1EMY/REB3U/L*?"_B"3X
MN>+#I]MITUS$ELL7VUR&2$QY_=\="V<^]=)X9Z#H'BO1_$HF&G7)::#'G02H
M4DCSTRIYK/O_ (C>&M.U&6RDNY99(6VSM;P-(D)]&8# KDY]+\3#QM'K4YTF
MUOX],N8V@M)29+@;"4)!'.'V\UO?"BVT[_A6FDR6ZQNT\1>Z<@$M*2=^[WSD
M<T -UWQ'X<\6:+K>DV6H23SVMH]R6MG=-I1=RG>N.Y'&>:YQ?B&WA?P)X&1I
M6DN;T6GVIY8GD_<,"'8,.K<=.OM3/!T6GQ6'Q/731']E2ZN%CV= /*.0/;.:
MANU4_#+X7$JI_P")KIHR1[-0!I>)M7TRQ^('@SQ(M]<06-]'=FX9I) CJD/R
M?N_7+>F22*[+0_'&AZ_?-8VDTL=V%+K!<PM$SJ.I4'J*Y_QI:P7'Q-^'L$L2
M/$);UPA'&5A4CCV(!I_Q#1+?Q#X'O(D5+@:VD'F*,'RW1@R_0X% 'H%%5FU&
MS69XFNHA(F-READ44 6*Y+0-"TNQ\9Z]<VUE%%,#%M91]W>F6P.@R?2BBHDD
MVCIH3E&%1)[K]4=;7E_Q@T;3O[)75?LJ"^+;#,,@D>_8_C1145TG3=SHRF4H
MXRGRNVIS7P@T;3M1U2>XO+5)I;;#Q%\X4^N.A_&O3/'VFV>IZ!&EY")52=67
M)(P<$=OK1165%+V!Z.:5)K-%J]+6\B+X?:79:9HUP+. 1>9.2V"3G"C'6N&^
M,6BZ=:2Q7]O:I%=7!S*ZDC<<]<=,T4454O8$X"I/^U-WJ]?,O_!_1-->S;57
MM$:^C.U)6))7/7 Z?C5+0;*-/BH;P27/VB2ZE1V-S(=RC=A2"V"H[#H***UP
MZ2IHX<WG*6-GS.]F:/Q8LH;[4M-6=IBL<9E14G= '#<-A2!N'8]:A^(-C!;?
M#[3?$,!FBUBVM8HH[V.9UEV%02&8'+#/][-%%;'FFI\(["WN/#Z^(+A7N-7N
M08Y;R>1I)"@Y"@L3@>PQ7!_$&$:!\2++3='FN;"QU.0/>6]M</&DC-]XX!XS
M[8HHH [7PIX>TO2?'^M:?86Q@LI+=D>W61S&P^0<J3C.._7FL73]'LI?ASXF
ML9$E>WTR_+V2M.Y-N4 V[#G*XR>A[T44 4KBT6]NO#=]<SW<EU%9P-'*;N7*
MEN&(^;J1U/?O6Y\5K.*[U[3VE>?,$ EBV3N@1PS88!2/F]^M%% &PVE65YK%
4Z+B'S-JQ,"7;.63)YS1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45876948725424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVS HEALTH Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000064803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-01011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">05-0494040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One CVS Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woonsocket<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">RI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">765-1500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME?,!\&9:;64:-N<0UWR:8FBUVS/<KK]'FRECP6[_EMG!>=JB2/W^91=CJU<
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M/UY_ 5!+ 0(4 Q0    ( +DU<ED'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ N35R6=;R?0SO
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ N35R69E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "Y-7)9I\.GY3T$  ""$   &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ N35R69^@&_"Q @  X@P   T              ( !@0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "Y-7)9EXJ[',     3 @  "P
M    @ %=#P  7W)E;',O+G)E;'-02P$"% ,4    " "Y-7)9'#AEZC\!   \
M @  #P              @ %&$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ N35R620>FZ*M    ^ $  !H              ( !LA$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ N35R6660>9(9 0  SP,
M !,              ( !EQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  X1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d828431d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvs-20241112.xsd</File>
    <File>cvs-20241112_lab.xml</File>
    <File>cvs-20241112_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d828431d8k.htm">d828431d8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g828431g1116064733982.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d828431d8k.htm": {
   "nsprefix": "cvs",
   "nsuri": "http://www.cvshealth.com/20241112",
   "dts": {
    "schema": {
     "local": [
      "cvs-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cvs-20241112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvs-20241112_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d828431d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-11-12_to_2024-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d828431d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-11-12_to_2024-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d828431d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cvshealth.com//20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-260405-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-260405-xbrl.zip
M4$L#!!0    ( +DU<EDP8$3,0 ,  $T+   0    8W9S+3(P,C0Q,3$R+GAS
M9+U636_;.!"]%^A_F.JT"ZQ$RTX6M1"G:#<-$"#-%FZZV%M!2V.;*$5J22J)
M__T.*<F1G=AUDJ*^F.+,>WSSP9%.WMV5$F[06*'5)$J3002H<ET(M9A$M8VY
MS86(WIV^?G7R)H[A[/SB"F)8.E?9C+';V]NDF MEM:P=,=@DUR6#..[\_[K^
M"O\T[!E,42*W""6W#@U\J(4LLN%@>)0.!F^341]FD'L^*+C##-*4I6^9]X2C
M;#3.CH_@\R?X&&@47(L2^UA=K8Q8+!W\EO\. 72FE4(I<07G0G&5"R[A2R?Y
M#[A0>0+OI82IAUG2:='<8)&TK'>VR&R^Q)*_?@5 "5,V4T19EY/(9Z)-Q-W,
MR$2;!2N<86Y5(2.GF+S0B#SJ07^,>X"A2GB+70/GW,X"J+/X](QZB/S&;IQ"
MSTODTBU#B4+6TW38 Q0HUH @R6*>+/0-(\,VN;>+QX,8#@8C1AWA*,_8@TBA
MON]!>/.,FJ-_R /([2@ TO%XS()U2U+A-B-HV8]98PS>W#DC9K7#<VW*,YSS
M6A*J5O_57(JYP")X4:>6J-R&SZ:'XV:![HJ7:"N>X]-R31WU6&"D-67_?KK\
M$IHM.O4 @-!_HJRT<="TX:7.P_78DT__%'=EB/U6G [C49H0603J4=D[:@CL
MQ4*ZZCY+R+HU#A9B=[6P7\1^L>OTQQO_V1G8OM$^_K&//_WSH/@?3(2?H$2K
MJY>*Z8VUY]=$<9$W4ZM9'EZ7>^2+>K,;"SX/QWL/WIXC[:GA3*Z4=N&@OA)>
M54+-=;M%F[Z)LZZ3ISB',+\R;G*C)>Z?<JPRND+C!$WY^\O0$"P-SB<1#9RX
M&S/?))\E-&8ZCP?\F[?+FQE!4%[>J^NP3C@/OO1F\'9Z6W*YIO;=,(DLI5WV
M;N>OC;8R^-1H"6)IN(>B[0[Z<\_KR;'[<Z[) _SBZ_1BS^MA_7Y@CM]II<M5
MH_),Y[5_!W7_[U7Q49&VU04UEBF#K@@$O4BFY/[M(/>URDYG@?3U)D+WTD<8
M_>CCKF/H+[DJH*&#'M\)VR;9YJ\M%G^KT[#.N<QKN<YZ"VX]]@&WZW4X\E[9
M;ER[VU6LN\5L^QJW._WKWFPUXX8>_P=02P,$%     @ N35R67Z9B==A!@
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M*L<?QW$C,G0EA<S6D15%MS)99"",^^R(]$X89M8],9$JR[L2D#RKK9F"23O
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MSZDX\]F%(R&J2_!5VP[D_[ 5<A,=I.8!"^QCDYLC]LT^!(@E?P%02P,$%
M  @ N35R6><\C,L=&   I80   X   !D.#(X-#,Q9#AK+FAT;>U=ZW?BMK;_
MGK]"B[:GR5H\;" /2"9GI82929M)LD+ZN/=+E[ %Z(RQ7<F$</[ZN[=D&1LP
M$ ))IS==G9F 96EKZ[>?VE+._OTT],@C$Y('_H<?[;+U(V&^$[C<[W_X\:+3
MNKKZ\=_G>V>#")I!4U\V7<8_% 91%#8KE:>N\,J2.>5^\%B!!Y6J5:T5XH8C
M68HF(9-)ZQZ5W7(@^A7S)-/<#WQ_-$P:C\?CLNH>7W C4<$W*M"H!*V8X(YY
M[\GC_M?,:^.:>LEN-!H5]=0TG6N9#%"UK%H%'W>I9*:Y\R@SK>'S@%$O&I2=
M8(BTUVW;KB9T2+Z("NC9KOSQY;KC#-B0EK@O(^H[R1BC2.12U*C 4].0RZ!>
MM8^7D!^W2%YXRFMK0UL?)LO^^.G^>MH\6MQ^VK02">K+7B"&- *X8$^'):M:
MJAZE.BD!'#(=&7BLZN>D5+,37L+@?-E49[B(3]T96,:-CRKZ8=PT'R@(\0)"
MG5$7_HEXY+'SD](O9Q7]X][9D$64X.LE]M>(/WXHM (_8GY4>@!H%HBC/WTH
M1.PIJJCN*O!617=("#GK!N[D_,SECT1&$X]]*+A<AAZ=(/99X9R<\:<FMF8B
M_IF[+O/US]#D1@.?</=#X;-Z]"?(W)]M'PB<W+,^E\C8Z(8.@1H?_H8!&&\N
M?JZH?8KN60]:C81:B3\1TR7;+MG5/Z,@]:EPWOJM0SZW+ZX?/I-6(,*S2H:D
M.1*GHU\,F>_"G^BC1_O/'59-E3\]EJK'QX7S'O4D6S7R0N:T8'Q!O2O?94^_
ML,D\=^8:/),]%OYW5#^Q:O/T56964K >$Z!DF83/J'.:4ND&&&N7*DV-A$KT
M0T'R8>@EWPT$3A*46\FHM/*3=,U3*AP1(%97CU&))YN9H/HL@Y'0'Y5D-V/N
MJL5:@[OF-:;6*OG(7?RBQYD@BH-LH=YI7?V279_9EY'JA?V'L("!FWP$E2.B
M2QJQ\REMYLWILRFM;DY;\R09-AFGDN%.PLTI]RII!5$!10+_I-0)OE6B'N_[
M30?FPD0A^WS,W6C0/"D?<O\TU=9CO>AT2$6?^R7\N4GH* K,-X+W!_%7V%UH
M.D-M7AHP]13\AC#I(@K"9NIC-XBB8*B^Z08"2#??V.$3D8''7?*=6AZK</ZO
M[^PCZ_2L$N8-5%L]4'7C@5+=UJ$3,C\!TH.E*4G^7]:T3Y+//3KDWJ3YP(=,
MDALV)O?!D/JGZME8T]T-//=TP?+\>G/UT+XDG8>+AW8GGQSKE<CIM%N_WE\]
M7+4[Y.+FDK3_:'V^N/G4)JW;+U^N.IVKVYL7T5C=!HV_4SD [S0*_"*Y;)&J
M=5AOS% U,^0J7&;AL$J>%N+R:"-<EBUHEH7FJ9;1JOW#_-S7E-'I9(R*6+1<
M>C%> 5,?;^^_D#,94C]10P,>L1)\XS"PE&-!P\)YKO]P&3@C=!]2/M8&[L/)
M24'[<EGC?%9!NL[?X;,3^&Q%W$$AW;=O'LA]^^[V_N'MU<_=K_>=7R^ H(=;
M NKR 70BL6OD]I[8A_N7!V]/X.U'\O"Y35*J/%'C%ZT' H_M1JV>3^>KK2PZ
M023H$<'"0$1DWWQF%)P@)B/"'J%E_)BY!\W\(,,HB3OE2;6U@_5L;:$C4M08
M4=.%#H;P^L"EDPE0Q/RT-FD4SF^"1S;L@NMI5XL$>YG7+>]*91VE\B+&Y G:
M/'P7\&WOC _[1 KG0Z%_4CVIU^P^1#]'$"<<UVJ-DVKY/R%$K-0#2%S??KJ%
M^"9W38^V1OERR:O6MR%Y67-,,&53XD\E':0V5Z46,KF VWM0RQ</RC-4MI2\
M2 -:VYC>?ON).A%!8E&?3,DG5)).R!P,^US"?=(:0-C&Q*S6?I?5'<CJWEE$
MNQXC#O,\]/TPPURP"NIS2%W7?(Z'BJ?J!)Y'0\F:YH?E\$AA"9U7S0S;LGZ(
M6=>T8BJ;EHEH@2ZA_G:S87*M_@-F--(/'IF(N$.]F*MZHK.-XK>KZ[UM2)QK
MG>[FK!*3*,S3D/99J2L8_8H99>ZR)GT,  5K<\=6RY,9D:0 0S*(:2JLD)D)
MP+*#WY[6)+/"N<2MUYKERG<" >9=6>9.!#:W%8S\2$Q:@?LB^XTJ#9,R$0M%
M\(C#9@QXPP+W@WET#(8]-R:(W'56/X'X;/.=L'/C,$KS^R/W&#P#MV7S4*IA
M8SK-+EFV9=NYS/OG\O"!/EW%N4-',>W%#,7\\6')JC?J5MU:@Z,[4 <GKZ(-
M]I6(DT"0VV@ KO//(\&ERQWDU%E75,[!6F=4PL&; FE3+V8K:9/]5C <<HG[
MLL_RJ.P=T()J@VB8'VB_X&\HU_M7Y?MRITS:P] +)DPH0&4EE=P$Y8,Y28*_
MT#%Y03B\%:]UA=JY<%W!I(S_N0;?T7Z!RJD5SF]]1M"3OQ3\<8$1?&LG?CUV
MM.#'6_$0C/T7,*->./\]"'P9.%]9-,N)8G[6(4.)4FVWX@[<#:YVIG?GO!P6
MSN\'X""1*^E1WUU_+S9#\%T 0WC_R\.-?*TI-4=@O:HGC<-M0F@[&C2>*,:
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M:&@Y^MJRN;T<K\EX;2NC94]K*)I6*K<UGT.;R;&M%2P6%N6?ZC^<+G3%\^S
M[X)'L%X8NXS\V.N6+_:%ND'@=2FL503(2MN*!O*[<5ROG\Z;BA4ARFR$1[)+
M2UZLC6<*;,#'U+P!9J290\*1D".$)P#\?@1PJ5</8Z@B1CO@KL"+'/J^<"*R
M;Q^3UL=[4JU996@X#<?R0IEW_#X'OQW0Q0YPV^]_ 44&VLS;%7AKN@SI6P'O
ME#'0M>;,/')7:GB[3E4AG%;R4Y"WG[1MST!\96_5NE76/1ZD/,-W:=B:--P)
MAIH<2SE5"0X:8@%ATP;^_=I287]+4K$2HL#!DI-BH8%^Q@9L)$ANJ;K?/=BN
M*.D^WX7I-83I2LH1$Z\B4M5WD5I'I&JL5-]WMBM2<9]KB]2V4P*+:GRG#J6.
MC9B Z"K-+VB!/-3B:J-*, $3," _/GHO"?BV2P(VV -<(Y^1,\4% O.F6UP/
M>,9+5Q\Z ^)X5,K7V>G:E(5OS2]!43S5)EMG,H1F^_*5]@9?@6.[R'J:<C0%
M,!:;E#??V@53";((%$UM0=9(_4W+CG(#>&W=)G:UJT1ZXXV(FE4KG*/#!ASJ
M1('SM4A"*L@C]4:,?&^5+9N$>/!LL+"$Z$WVQ_-X$LNJ%M,7,*2N2C__YI,U
M #!.VR:G7>=<:Q37V7W8FG4(0@T@_Y] ?-4023S%A3QZ)9^O<'[EN^@&,]*=
M$$<EZ*''KR#G3%7=S&3%.>ZY$'"E<= ^Z8M@' W0FPXQ4TXE<5F/^[I>5N<G
MK4/C#\XD)^%;NU&K99.4IC6, \P)L=P6*X#6=,JKW5*2+YH?-..9Z]'KS_30
MYP9(T5G>[89=X;R=P_45._CFM4_JK99^:7?QX]&2^'&W_+GJ+<%F$1"Y$.A\
M;N=G #!F'H0U &,_4$'.2#+5"A@6[R_AI01<!X_J& DR2(WE37#P,8>A<7%\
MH ^>"/;();P'PD%]!_.AU'&P>A4;X_4$+A6NU#M+[M((J[9/DP@KC>@R2=B>
M%W*M<^QVC6.UW_#Y7;W'&>]T[NTM!B,;SF$1OTJY,UT&JPWNC#>F$UG0IQCV
MS@:)YP.Q9B":WS74?Z=F-N%3.IYT/$8%FKN!BMSV5FPE;_=D]M[KE6N!7$9L
MB*4/EGUJHR?4QIIMW*H-""5FYX1<HN'@JM;FHB^8RM:4EYP/.=J&RKC%*C]]
M-"L6KV-]/JNHJMT^JPM<U!T6<8TIV4>YP]E4K=-8EZI/]ND!44NE;)^:&FC8
MGKXX -8G NMHIC732;95,OFD6Z5+/GG,?^1 >8N&/ )^?:$^ !(;%LGU=8OL
MQ_V9AN;U93S<CMY]@,GDSL*H-(D*LD@H>,A]$L2N!2@_652:##UCM27? Z=.
M1)0G6_(I)JO:F317@=/)Q3 S;,+*$#X, \GD_$+ ,\$\B@I^6@,@"722?3\"
M;Z>'Q0+05,:OA8))Z(HB4J4>%+X)04>KHH,11$<IJLKD+J7)HV6<*J:G2Z@G
M XT85<S ?0<T3VR%<&'RV/-3 (8$'UYR 30%0F;0IAXGR )+V M&0LT,(1N&
M 6"77#/I<0:2(<;4@U#FF@H0V/N@VX4XKD@^C2:D ^8/ZY?PS<M@U">=P<@#
M-)A9JG'*9$UH1 ,:968_YIX'MG<(UA(,M@J"84I?9%E+:4+9%Q%_DQ"7?).F
M</IE3"4::V7B$3C9L1-.@AHXA+?]$> ,G/DHAJ=$WWT BHT)#0GT#1 IN#Z!
MKU*4774@M0>CP/? $8?&#@3/#JO0DAW"\&PA"LP"S3+"<#W65QTF'K%849'W
MP" : 7O4GR0JXG/G7W08GCXD.%#5XU'$$E1I%&59%_,S'NIBY/(HY\7=JYQG
M"-5S)7I P0*E6-Z%?I7+&*LE9P0( /HGVFV3$4(5>HB$/IH &#0YDB&VA_\!
M":@>T-OS%+F@^2!(A0"+N'0"8L !CO%,TIL5AJDIR!$W%FLC'5KS^6XP5J#.
M ?+1"B 7 8K=_\0Z3!^IAKZ82(; B<<,\#@L.3#'X<(9#?756A)#/\DBI"%"
M!;A\569 #JN0K))F?Q;V9N25,1I>^(:W9%$1F\8D5IMJ^=>QA^@?]@/D-.@W
M1_!0<=$-H"6&%.#>JV/L,+DNTV$#B[2N@HCR+UBIY-0I0A99*!AP$'"8W)=D
M$-,; 0#5!4F)2<@5!G1*0E71IC&*X7P4@7J%L< D,P0\!LH#W@7IMB'B-33Q
MY*1-W!1(2U.SE*TGN_8K#\M6M0PN)*Q\-!(L:_] +%HQ@G05MY"GI&W4<+KI
M*;G0&M9(W_Q["%KF2PK-@;-"8/B%K>6BYCOW7Q%J:1\H(X+('Z(\[I>NWU;$
M8HFOO3W#/H;9&#.IE4?**EUA.9WOQPNO7+>X&-6LN5K%!6/GT[>,FN*<MZ;M
MZIC*Q*%S24\$L$Q5I-4^ @6-# +DS-EX?&MN9L:4YUCB!80N[&:9-<]A]*)N
MIC$)N?/ XJ#^4QXB>V1>$.K8)W9"OMPIRB]7."&[QV7[R6%AE+*>R_QS0)>"
MF ^*,B/\0I< *)\ PYI,!D<KVXU0#AT_#^2SEA7M!QAWR5T.(99Q<$+*W7F(
MQ7:;]F'.??2\59WV$\<B/F]"OK</&T7[V,)V>!FKZM\9"5 @$3P.QG,O5&VK
M:%<MC?&?*;@@8A(+OY9]&$] ^#"850V'\6-<%8P5I79IT3IACN\I!$V+$NSC
M*8",<Q*9DF[N/P;>(T(P6L$2T PJLXW=JJR?BD?F!5![>@[CBH$3O?)J:JM&
M2.:!65?NC_!<PJH9)7P%>Z-.ADSG5B8Q:!=Y71P<2)?K!0B17/4R>KCJEL5B
M?"("FW892(X?^X/XA3HFD3E)H3&O,--ES$?@F] 9C>U$9T*I=GVA233&5K/\
MV!KTU<J,@Y'GHN.D#W2HD$L7X"B35[?J<8[TGO5'GD;#2M^Q4_JEO/I6DNVH
MG"W:.\0D+@3' VL1,R"0N'_L&%]%I:E%T!=TB) Q\?2B8$&G9M;RM)D^.\L,
MUTQH(E$)<9F,:#3K,%!G<#"CF<882IYVDKL *KV.*\>/C<@-D-&>(<-X<U-7
M327/E9691B;96:/24@%=I*T7DHPRK'30BAP 1)- =^)-I#:<<,62%/WTA#;F
MF2X@Z//T4L:J;O>&[L)UU8X%];Q)D01S[EC5N&/*E,?F.666E6Y_9.@03/-1
M,4,S4 ,._0S>.'T$&_-S,/'Q@!N?][T0(RG?"Y%Y!X&T,KZ*=ZT!9[VY,YAB
M!KHXDUM8\ 5^I0Z\\56J/#N5;\'+NLKD(N6"I81-DYO@(E[Z*,",J\;WS%1#
MU$ C'ST%)8LP2<FE"AZ 3?'[>.$MB*2'60-X\+U=/+2LH@5_("*+8%E9E#0-
M_)',=(LOU%1C^$/VV5^:(IBB]0,^1#:J ?(W?M+Q5WZ>/[U1LI?>*=DC>^^;
M);O8+(&^-2H.%-X3+'B!WR]A^L6@ BVVKX$\5OG=%#X20'QOUPVN -^80MFM
MC(.P#DFG3#H#.EA7P*?"_!LZ/UEY_P2N8)CZ;H[\H\T%&XG<O5C;SQ-KN]BH
M'LZ(M7U\F!7KER,$AVH8#?(*=@:@]R+[HM+,T"N:Y6&@$QNJ8D9-33O3R9Y
M5G//>DET$/-MI4<!@Y9P4.-&"(;W\ZM$O6(H#OK /?H5HUR7NKRXT)/0-NN2
M]W&3K@A&,*)%<@$V=P(NVEQ&/K9H13T=731 ^JH*P8TON,PRL689;P'CO)@?
M@)HUV" 20<9\$78-T<&0CX8E\$4<C$@4CX-0N_*8"G3^&H%PZ+(UG>"*3:ZC
M2]VD+G6;IUL7OBF(5PWPBHD>053/+YV^6N'[H]7M<3Z: 4MGH 17YY,QP&+"
MX1)?0<4S%;>JMJ)J("^0^GPO-LG=?YQ.?1[DU4;1.(TN><1M(#4)P<R0B;CB
M?1J>#B'=D3!AJFZ*;K%,'3C&)U/N%DF? ;_0C4NG[75]2JQ>T]NE<<"IW?5A
MK%@5X)! E:-6FC/A;PSPJ;I4 J"2B!G\H+B43!]F"R19!M0]ZA6S/;H1?J:>
MC^&HW %+TWQ<4U=@AT97A!#9*$80# H4A%114,Y*J:JQ]=?E+1/KQV7++J?C
MZ(^7H-PD2LI(+*5M1_49)VDC8N#$\7@4:OE0W0HAF*?\%@!&,/(=L]PTF]O?
M7A">3L#IO?0%>H--JUY6[(U=))LTD59QJ2DMW[!I-+:T8;.ERE)5Y"9<W"&,
MRS.T.) KD%4QTJ[B3^4JSG7M6Q^*1NJBF<T/I19@YBH)A,!%"V*N54FSJ(@6
M31481)A%<I'QKJF04.&\21>8U(7:KY/:!F;+\4[6+#0MJD3?4%4/%C&UI1(M
M8[1(,SK<X[3+/=V3ZAL+!?28VN@MG7-V:AD09#8/=8T2R(ZY"R.FB+CQ[=B9
M!'9^^6YV7FR:EE1D=-$D*02C!DPRE4")U#?K.AF2M!\_I<C0\K8ZL*%TX,>D
M<K-CTD0FPZ.0M=%FGPI(N8]Z (^(/D^^YJ^X4S\WT?/D3N%\WSU(B,O);+[B
M>;R?;N\OV_>EUNWU]<5=I]TT/SSOU.X:!_+V]O21//6/6XG_7><072/G$-W)
MR:L=HEO[ !Q1#3X4%EPUM-:QVS7.11'S"\?T+V,K=3WPUIYUIFA!:B8&9&QY
MU>U7&QP$RSL=LM'YP:WS2\E%">7@.=S"2X:34I'LL:H8T@ND=@Y YHHI>%#)
M?0(.!HHLP*?Z:A=&SY_+6;@N6'.R&S#HDT"4Z-]@YNH[_%WV9(-V'T1#/+^5
MN_/K*@.:5[[0U9M<>9M?JTIWT7#0O$-T_^2U1E_L==>ZT8C7^DYYU??:J\Y9
MWSC4(/N]D?"Y'"2[4XFS=?#_=NELJ[[#E6O!0@AR!].#2 ',!M6Y7DRF$76]
M<"E.2&,SY +!WQ1*(MJ7*L^%J^BZ\:Y<G+2X4D9,-TS\RI2*77IER08[*&3)
MML'<BV3.*WCY;__8Z+Z'4K6D?<2]]QV@-SDNL_ 2CJM/-Q</O]ZW-PG97Q1B
MS-99"Z8RPDFIW%J![X+C=>X(XD%5%>_J^#7^M4ZZ'E;"Y-4V@-J#[S(()7MH
M9+$C766E&ZC:E!$&LJH_6*M!(&!F\T5C_X0X9S:RR<*[KFX;63_6R;LP9-UN
M%K]]N"4BZDG ->/ZOH+)B^<W-;XU_=O'FCG^P8N/M*\Q?MXO4=K4[T IR'$\
MU*.LY['=9F_BQRP&[586:JM]*O?GITES1Z!ZYO4A*T[6/M.85&2%_"(X;FU0
M\IO*J'U]Y>M#OE%4F.9X/<76H:$@-[\N[VNR!MO4K3&[69$.\_%86+9,IAC7
M%WS"R,=7^RJF*$X5S)ED/SIE@D543!9%.-]F9%++BTS.*MW G<!GB.R]\_\#
M4$L#!!0    ( +DU<ED)0A*()2X  /+0   1    9#@R.#0S,61E>#$P,2YH
M=&WM?6E3W-:VZ'>J^ \J3N544R4P8#QA0@4#MKD'VY0AR<M[]3ZH6[N;'=12
M'PU@\NOOFO:DEAH\Q,2)3]VZ,=WJK;777O.T=U^?OSG9VWU]M'^XM[RT>WY\
M?G*T=_1_UC8WUC=W'_"?\/D#>2#:??'N\+?HQ:N#=R?OWO^X\NOKX_.CE>CL
M_+>3HQ]7,IVKM0NE)Q?USMNBG";9REZTO 2_/U!YK<J]W</C7\S#USJM+W:>
MKC_2^4J49'J2PP)J7*_0:T[-8].DG.A\K2YF.QNS^GDD?P^+NBZF_-&XR.NU
M2O^A=C;=W^-DJK.;G7,]557T5EU'[XMI F_:/SE^]?;'E1*!7-G;?;%W].%"
M#W4=X8ZCW0<O]G8?G.*6NR#8W/J"((P()RM[![^<1:]5DM47T4%1SHHRJ761
M1U\+#,'$V^)*38>J_'<^K&;/-Y_$T=;&UC9!T7T:7P2(O5>9RJ\T_'V0S'2=
M9,M+;Y(\F:@I(">.3DX.%D#P)>AA[\GC)]%+/0;D[U^IO%%QM+T-?[S,BJ+\
ML]^-__RM*"_CZ.UORTN;&YN/'O[9K]RO:\ LT-=.]"8I+Z/715E<Z_J//_N]
M1]-$9SO+2[#.Y4\3.?01G_GZJ)C^Z81VDJ0:/DGR-'H%&,B0PG86O/7QEWBI
M8^WE)8^WXRB)#E667">EBD8>SP_J"Q7]^U^;VT^>[_Z\=U!,9TE^L_O@YSW\
M[.GSU9CA;_%,U&:905U,%"Q51G"T%Y&NJVA_/-:93FI5Q?X+&A1!LZ2LO;=$
M0/CVD9NB<=_PZ\/%$6(!-(Y4,KJ(DN4E^_/VTOC[49%E:E3K*Y7=1,&&\6DX
M)&_#$<E(E48ZKPO 6J: ?LLHF91*]IO"GM+HW:@NG/#:%.$5HO,=2#J= [K>
M'NX'.)V Z"MSG4\(FNHB*?'?Q3@:J;).= XO'Z,VHR,:%?G(>UJV3AL#/"\O
M5<VPTJF&-83:S"+PP[%.D?E V=7\BX+P6 Q!^]'J5<0/YH@?>!E^K1#-Z]%Q
M\(5%?3*;%8 ;Q 5"C!^-BZ:,9JJL<+U45:-2#PF#\FTYQ2=GI:JJJ%292BI8
MIJ[AZ!0>+CRE*X?A**DB0)[1DH0Y@GW6E%63P -U 6KJY[TS!@V_A[_D/WP@
M3_&O&" 894V*F#M)RO(&F&0XU !C>$R6NO=Y:TH%AT4 JNA%D90I[N-0E_#B
MHJS,]LV)A*O2\^%"\+40'&()EL&U$]AS2OL#_-1 6_2<3SJ(2#II/,I2X4E6
M4:5JQ"P<"IZ8SLUY 2DHX6T!;P3$E@/:F#@LFN>78 AA<TK/:GJX:H")1UKE
MHQM<[?I"([<!W/B#(< QNLR+ZTRE$Y7&'7!7]D'<I JVF<JV(G]78^#4XKK:
M662+],G)6GVHUW2.!+^S_<-'RLW-]8C$D^,8P*?E03S&]>C<.^L&WE/"/O+4
M0RL0%OPDND%V&*I<C36C$3]$Y)C/Y&#FZ6X5/D_JF'CZ=R R0WL@@:9(;BP.
M 6_)"(1XFH!@,(SI<U#<LSQ@[2:0"B .4UV-L@(8TA<YQ1 %"!P1G'@& DJ5
M5\A$<$!)-"6CS>R!N0+ A$W[_$8X>*^0Y^%5"<K>BJ'O@:&I2)0!??F T.;H
M4Q$O<=2)&I;R>:I9IA%P/D;6HWV$':!I,D /0$<_Z8*2 "0FN%)6E.Z^?/?V
MW/H1%[I6:]4L&:D=(/\RF:WLY46^-FM K(YV'^"S>\$V2C4!-+4D.!*4ADW[
M#P+,L[*8@2BO$Y!7LD=?Y"-TC&8XEQHX74WT*(Z&304'!O(52&T,#)B/D(1G
M69*3XO#>@:=4*U*(#3X"KX--@BIU/V,T :[AR]]9R%:&D-4HJ6IZ39)>Z9$R
MJ$HC8',^*1%Q\ APH[[2*;P'6+L$FPMV@W8);0?EXN/G%6J"HLS5#=('D#48
M""BL8A)F  9)+EB+-1>^M +9"R1>)H@"-0+94<4AU9"<\C%W :1KB5H@T4"X
M!E;<'-$:;'TFU#6_BJZ,YH15 "3U 9]E'0;69MZE==?!WFZ8$)>7\#Q+!1PN
M9DTT2AI@O4XR])[-LH\P"*+ 'D!Y@G#[4,6?0LZP79\R!]<7;)(!T(!$/O[
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M=;!4V=]:CB35RU) OKTYH.I/SAJM1_M9MB#V+=XUUD 8JX6*^):7VM4M7 W
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MD@"3E93Q)6D.VPP3S,,;OA%JL&T"$#;A;280\(,7+&Y(&*5],@I_<J*J3"M
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M\<TG]2&$\V_R@7S6K)Y#_4W05FEN;&&)(9"CI,]0(,8U  W 7@7YSU4$QVE
M0->=_T6G7GQR(>QK$U\K<==R@C(1Z YR7!S["PBOAF7H#,0@Z[7\8UN#-GYT
M\1YQ4(#5A@.^JH!Q7A+_/#129)&N'NYF/J-S$]]?H["@-G;<3YAO^U68;W<D
MIK+"GIEMJ=]$44(B*U?14=JT]4G706XKE7X(L6TB.I+HA#?MI4!+:]=J"?I
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MB3K>2]]EIEZ5P>J^Y*4KR!?;VPFAMVO^=O>$?)N\L]^+I$Y.O?2/>;$&'09
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M=0/C,]I&)W1TM7\< ?'S\R/@""E!02EM192B]O\<;C> Y -$@0(P2 G@08+
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M,C R-#$Q,3(N>'-D4$L! A0#%     @ N35R67Z9B==A!@  OT,  !0
M         ( !;@,  &-V<RTR,#(T,3$Q,E]L86(N>&UL4$L! A0#%     @
MN35R66/3W^BW!   ?BH  !0              ( ! 0H  &-V<RTR,#(T,3$Q
M,E]P<F4N>&UL4$L! A0#%     @ N35R6><\C,L=&   I80   X
M     ( !Z@X  &0X,C@T,S%D.&LN:'1M4$L! A0#%     @ N35R60E"$H@E
M+@  \M   !$              ( !,R<  &0X,C@T,S%D97@Q,#$N:'1M4$L!
M A0#%     @ N35R695CY#!V$   &2\  !$              ( !AU4  &0X
M,C@T,S%D97@Y.3$N:'1M4$L! A0#%     @ N35R68^N2VM6"   W@@  !D
M             ( !+&8  &<X,C@T,S%G,3$Q-C V-#<S,SDX,BYJ<&=02P4&
2      < !P## 0  N6X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d828431d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvs-20241112.xsd" xlink:type="simple"/>
    <context id="duration_2024-11-12_to_2024-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2024-11-12_to_2024-11-12"
      id="Hidden_dei_EntityRegistrantName">CVS HEALTH Corp</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-277">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-11-12_to_2024-11-12"
      id="Hidden_dei_EntityCentralIndexKey">0000064803</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-288">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-289">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-290">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-291">001-01011</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-292">05-0494040</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-293">One CVS Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-294">Woonsocket</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-295">RI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-296">02895</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-297">(401)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-298">765-1500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-299">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-300">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-301">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-302">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-303">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-304">CVS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-305">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-11-12_to_2024-11-12" id="ixv-306">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
